New Drugs Approved In June


Genentech, a Roche company, on June 10, 2019, won FDA approval for Polivy, for the treatment of adults with diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies.

The new antibody treatment, Polivy (polatuzumab vedotin-piiq) is approved to be used in combination with chemotherapy drug bendamustine and Rituxan (BR).

The dosage of Polivy will be based on the weight of the patient and a four-month course will cost about $90,000.

Analysts at Jefferies expect the drug to rake in $1 billion sales at peak.

The drug will have to compete with Novartis' Kymriah, which had $76 million sales in 2018 and Kite’s Yescarta that had garnered $264 million in sales last year.